Study reveals impact of Demodex blepharitis
The results of the Atlas study, presented at the virtual Association for Research in Vision and Ophthalmology meeting, show the functional and psychosocial impact Demodex blepharitis has on patients, according to a Tarsus press release.
The multicenter observational study included 311 patients who were screened for Demodex blepharitis and had three objective signs of the disease: the presence of Demodex mites, the presence of collarettes on the lashes and lid margin erythema.
Overall, 51% of patients reported having signs and symptoms of the disease for 4 or more years, and 58% reported never being diagnosed.
In addition, 47% reported being conscious of their eyes all day, 23% were “constantly worrying about their eyes,” and 23% reported their eyes or eyelids having a negative appearance.
Tarsus also released data from Europa, a prospective, randomized, vehicle-controlled phase 2b trial investigating safety and efficacy of twice-daily TP-03 (topical lotilaner ophthalmic solution 0.25%) in patients with Demodex blepharitis.
Collarette cure was achieved by 80% of patients on TP-03 compared with 16% of patients on vehicle at 42 days (P < .001). No serious adverse events were reported, with no discontinuations due to adverse events.